Sangamo Therapeutics draws $7 million in bankruptcy financing
Sangamo Therapeutics posted a $14.45 million August 2026 loss in its Chapter 11 operating report filed October 14. Restructuring expenses totaled $9.98 million, while month-end cash reached $23.23 million. A $7 million draw on August 21 came under the replacement debtor-in-possession term loan facility, authorized for